Clinical commentary on “De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine”

Abstract

Keywords

Fampridine multiple sclerosis rehabilitation symptomatic treatment seizures status epilepticus

Get full access to this article

View all access options for this article.

References

Goodman

Brown

Krupp

et al . Sustained-release oral fampridine in multiple sclerosis: A randomised, double-blind, controlled trial. Lancet 2009; 373(9665): 732–738.

Goodman

Brown

Edwards

et al . A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68(4): 494–502.

Panicucci

Cohen

Bourg

et al . De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine. Mult Scler 2019; 25: 618–621.

Fampyra^® (fampridine): Summary of Product Characteristics (SmPC), www.medicines.org.uk (accessed 20 August 2018).

Jara

Aquilina

Aupperle

et al . Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States. Drug Healthc Patient Saf 2015; 7: 169–174.

Lund

Nakken

Edland

et al . Multiple sclerosis and seizures: Incidence and prevalence over 40 years. Acta Neurol Scand 2014; 130(6): 368–373.

Gasparini

Ferlazzo

Ascoli

et al . Risk factors for unprovoked epileptic seizures in multiple sclerosis: A systematic review and meta-analysis. Neurol Sci 2017; 38(3): 399–406.

de Gusmao

Ortega

Wallace

. Status epilepticus associated with dalfampridine in a patient with multiple sclerosis. J Neuropsychiatry Clin Neurosci 2012; 24(4): E47–8.